Abbott Beats Q1 Profit and Revenue Estimates, But Cuts 2026 Outlook After $23B Exact Sciences Deal
Abbott beat Q1 earnings, boosted by cancer diagnostics deal, but cut 2026 profit outlook due to acquisition costs.
/ 4 items
#ABT↓
Abbott Laboratories Stock Plunges on Nutrition Division Struggles and Weak Guidance
Abbott (ABT) stock fell 8% after missing Q4 earnings expectations, with nutrition sales dropping 8.9% due to lower volumes and strategic price cuts on baby formula and supplements.
Abbott Makes Major Move in Cancer Diagnostics with $21B Exact Sciences Acquisition
Abbott to acquire Exact Sciences for $21 billion, gaining leadership in cancer screening with Cologuard and expanding its diagnostics portfolio into fast-growing oncology segment.
Abbott Laboratories Eyes Largest Deal in Decade with Exact Sciences Acquisition
Abbott Laboratories is in talks to acquire Exact Sciences Corp. for ~$16B, marking its biggest healthcare deal of 2025 and largest acquisition in nearly 10 years.